Intensity Therapeutics, Inc. financial data

Symbol
INTS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
61 Wilton Road, 3 Rd Floor, Westport, Connecticut
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 598 %
Debt-to-equity 20.1 %
Return On Equity -102 %
Return On Assets -85.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.7M shares
Common Stock, Shares, Outstanding 13.7M shares
Entity Public Float 22M USD
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 13.7M shares +302%
Weighted Average Number of Shares Outstanding, Diluted 13.7M shares +302%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.83M USD +264%
General and Administrative Expense 4.98M USD +302%
Operating Income (Loss) -11.8M USD -278%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13.8M USD -245%
Earnings Per Share, Basic -1.33 USD/shares +12.8%
Earnings Per Share, Diluted -1.33 USD/shares +12.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.46M USD -12.8%
Marketable Securities, Current 8.96M USD
Cash, Cash Equivalents, and Short-term Investments 10.5M USD
Other Assets, Current 6K USD -92.1%
Assets, Current 11.2M USD
Operating Lease, Right-of-Use Asset 141K USD
Other Assets, Noncurrent 1.1M USD
Assets 12.4M USD
Accounts Payable, Current 1.22M USD
Employee-related Liabilities, Current 407K USD +3.83%
Accrued Liabilities, Current 1.27M USD +43%
Liabilities, Current 2.52M USD
Operating Lease, Liability, Noncurrent 131K USD
Other Liabilities, Noncurrent 36K USD
Liabilities 2.69M USD
Retained Earnings (Accumulated Deficit) -55.1M USD
Stockholders' Equity Attributable to Parent 9.72M USD
Liabilities and Equity 12.4M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.37M USD -385%
Net Cash Provided by (Used in) Financing Activities 8K USD -96.1%
Net Cash Provided by (Used in) Investing Activities 3.26M USD
Common Stock, Shares Authorized 135M shares
Common Stock, Shares, Issued 13.7M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD -57.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.46M USD +1111%
Deferred Tax Assets, Valuation Allowance 12M USD +18.7%
Deferred Tax Assets, Gross 12M USD +18.7%
Operating Lease, Liability 157K USD
Lessee, Operating Lease, Liability, to be Paid 185K USD
Operating Lease, Liability, Current 26K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 37K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 36K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 39K USD
Deferred Tax Assets, Operating Loss Carryforwards 8.61M USD +6.92%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 39K USD
Operating Lease, Payments 3K USD -93.9%
Additional Paid in Capital 64.8M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39K USD +30%
Share-based Payment Arrangement, Expense 2.24M USD +270%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares